

# Zhiwei Chen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8797851/publications.pdf>

Version: 2024-02-01

17  
papers

572  
citations

933447

10  
h-index

888059

17  
g-index

17  
all docs

17  
docs citations

17  
times ranked

495  
citing authors

#	ARTICLE	IF	CITATIONS
1	The composition of the lung microbiome differs between patients with dermatomyositis and rheumatoid arthritis associated with interstitial lung disease. <i>FEBS Open Bio</i> , 2022, 12, 258-269.	2.3	7
2	Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 60, 293-304.	6.5	81
3	A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis. <i>Scientific Reports</i> , 2021, 11, 17070.	3.3	11
4	Description and Analysis of a Novel Subtype of the Anti-Synthetase Syndrome Characterized by Frequent Attacks of Fever and Systemic Inflammation in a Single-Center Cohort Study. <i>Frontiers in Immunology</i> , 2021, 12, 729602.	4.8	7
5	RNA-Containing Immune Complexes Formed by Anti-Melanoma Differentiation Associated Gene 5 Autoantibody Are Potent Inducers of IFN- $\gamma$ . <i>Frontiers in Immunology</i> , 2021, 12, 743704.	4.8	13
6	A Computed Tomography Radiomics-Based Prediction Model on Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis. <i>Frontiers in Medicine</i> , 2021, 8, 768052.	2.6	10
7	Serum S100A12 levels are correlated with clinical severity in patients with dermatomyositis-associated interstitial lung disease. <i>Journal of International Medical Research</i> , 2020, 48, 030006051988784.	1.0	8
8	Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease. <i>BMC Pulmonary Medicine</i> , 2020, 20, 196.	2.0	16
9	Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study. <i>Clinical Rheumatology</i> , 2020, 39, 3099-3104.	2.2	8
10	Systemic lupus erythematosus gastrointestinal involvement: a computed tomography-based assessment. <i>Scientific Reports</i> , 2020, 10, 6400.	3.3	6
11	Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease. <i>New England Journal of Medicine</i> , 2019, 381, 291-293.	27.0	237
12	Varicella zoster virus infections increase the risk of disease flares in patients with SLE: a matched cohort study. <i>Lupus Science and Medicine</i> , 2019, 6, e000339.	2.7	10
13	Two distinct clinical phenotypes of pulmonary arterial hypertension secondary to systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 148-150.	0.9	24
14	CD4+CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease. <i>Rheumatology</i> , 2019, 58, 511-521.	1.9	35
15	TMA secondary to SLE: rituximab improves overall but not renal survival. <i>Clinical Rheumatology</i> , 2018, 37, 213-218.	2.2	18
16	The performance of different anti-dsDNA autoantibodies assays in Chinese systemic lupus erythematosus patients. <i>Clinical Rheumatology</i> , 2018, 37, 139-144.	2.2	15
17	Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. <i>Scientific Reports</i> , 2016, 6, 33226.	3.3	66